article thumbnail

API Processes in the Pharmaceutical Industry

DS in Pharmatics

I earned a Bachelor of Science in Chemistry at Fairfield University in 1979 and a Ph.D. in Organic Chemistry at Yale University in 1984 […] Could you please introduce yourself and your expertise in the pharmaceutical industry?

article thumbnail

A demonstration of substituent effects in anti-aromatic compounds

SCIENMAG: Medicine & Health

On the other hand, anti-aromatic compounds with 4n pi-electrons have been conventionally considered unstable, and the creation of stable anti-aromatic compounds has been one of the challenging issues in organic chemistry. Several studies […]

article thumbnail

New chemical process makes it easier to craft amino acids that don't exist in nature

Science Daily: Pharmacology News

Chemists describe a powerful new way to create new-to-nature, 'unnatural' amino acids, which could find use in protein-based therapies and open up novel branches of organic chemistry.

article thumbnail

Analysis Chemical: Bavaria floats resolution in Bundesrat urging “PFAS regulation with a sense of proportion”

Agency IQ

This bond is one of the strongest in organic chemistry, making this family of chemicals highly effective at resisting water, oil, and heat. Manufactured since the 1940s, their carbon-fluorine bond tends to be the hallmark of a PFAS (though there is no common definition). Fill out the form to read the full article.

article thumbnail

Women in STEM with Dr Catherine Sheehan

Drug Target Review

My secondary school chemistry teacher had a PhD in organic chemistry, and I found her classes and lab experiments to be very interesting, especially those in physical and organic chemistry.

article thumbnail

Women in STEM with Dr Petra Dieterich

Drug Target Review

Petra holds a D.Phil in synthetic organic chemistry and an MBA from Imperial College London. Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinical trials and low-volume commercial manufacture.

article thumbnail

FDA Sets a Recommended Framework for Predicting the Mutagenic and Carcinogenic Potential of Nitrosamine Drug Substance-Related Impurities

FDA Law Blog: Biosimilars

This second half of this guidance beginning with the “Flowchart to Predict the Carcinogenic Potency Category of an NDSRI and Identify an Associated Recommended AI Limit” takes one back to basic organic chemistry and breaks down the key structural and electronic considerations into a step-by-step guide.

FDA 74